Comprehensive Library Of Resveratrol News

Comment:  Yet another poorly designed study that one might think was intended to kibosh resveratrol.  How does resveratrol improve normal?  If it worked (lowered blood sugar) it would have created hypoglycemia.  Resveratrol works synergistically in red wine in tandem with others molecules such as quercetin and ferulic acid.  Hence, a so-called red wine pill should attempt to provide an array of small molecules.  The hormesis effect where a low dose biological stressor triggers the body to produce internal antioxidants is not considered here.  Consider this study with a grain of salt.  Resveratrol has already been demonstrated to produce health benefits in humans.  – Bill Sardi, ResveratrolNews.com

---

Cell Metabolism, 25 October 2012
Copyright 2012 Elsevier Inc. All rights reserved.
10.1016/j.cmet.2012.09.015

Resveratrol Supplementation Does Not Improve Metabolic Function in Nonobese Women with Normal Glucose Tolerance

Authors

Jun Yoshino, Caterina Conte, Luigi Fontana, Bettina Mittendorfer, Shin-ichiro Imai, Kenneth B. Schechtman, Charles Gu, Iris Kunz, Filippo Rossi Fanelli, Bruce W. Patterson, Samuel Klein

• Highlights
• Resveratrol supplementation does not improve plasma lipids in nonobese women
• Resveratrol does not improve insulin sensitivity in nonobese women
• Resveratrol does not affect its putative targets in fat or muscle in nonobese women

Summary

Resveratrol has been reported to improve metabolic function in metabolically abnormal rodents and humans, but it has not been studied in nonobese people with normal glucose tolerance. We conducted a randomized, double-blind, placebo-controlled trial to evaluate the metabolic effects of 12 weeks of resveratrol supplementation (75 mg/day) in nonobese, postmenopausal women with normal glucose tolerance. Although resveratrol supplementation increased plasma resveratrol concentration, it did not change body composition, resting metabolic rate, plasma lipids, or inflammatory markers. A two-stage hyperinsulinemic-euglycemic clamp procedure, in conjunction with stable isotopically labeled tracer infusions, demonstrated that resveratrol did not increase liver, skeletal muscle, or adipose tissue insulin sensitivity. Consistent with the absence of in vivo metabolic effects, resveratrol did not affect its putative molecular targets, including AMPK, SIRT1, NAMPT, and PPARGC1A, in either skeletal muscle or adipose tissue. These findings demonstrate that resveratrol supplementation does not have beneficial metabolic effects in nonobese, postmenopausal women with normal glucose tolerance.